Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
Bethesda System (Thyroid FNA)Breslow Depth (Melanoma)Calculated Serum OsmolalityCorrected Calcium (Albumin)Corrected Sodium (Hyperglycaemia)Delta-Delta RatioFractional Excretion of Sodium (FENa)Fractional Excretion of Urea (FEUrea)Partin Tables (Prostate Cancer)Serum Anion Gap
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

In Recent Clinical News

Scanning Medical Journals

No new significant updates or guidelines matching this topic were found today. We will check again soon.

Breslow Depth (Melanoma)

Breslow Depth Analyzer

Melanoma Management Matrix

0 mm
In Situ5.0 mm10.0 mm

Depth Logic

Adjust the Breslow thickness and ulceration status to resolve surgical recommendations.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

What is Breslow Depth?

Breslow depth (also called Breslow thickness) is the single most important prognostic factor for primary cutaneous melanoma. It measures the vertical thickness of the tumor from the top of the granular layer of the epidermis (or from the base of the ulcer if the tumor is ulcerated) to the deepest point of tumor invasion in the dermis or subcutaneous fat. The measurement is expressed in millimeters (mm) to two decimal places and is used to determine the T category (tumor stage) in the AJCC (American Joint Committee on Cancer) staging system. Breslow depth directly correlates with the risk of lymph node metastasis, distant metastasis, and overall survival.

Primary Clinical Applications

Melanoma staging (AJCC 8th Edition) – Breslow depth determines T category (Tis, T1a, T1b, T2a, T2b, T3a, T3b, T4a, T4b), which combines with nodal status (N) and metastatic status (M) for overall stage grouping (0-IV)
Sentinel lymph node biopsy (SLNB) decision-making – Breslow depth ≥0.8 mm (or ≥0.8 mm with ulceration, mitotic rate ≥1/mm², or other high-risk features) is an indication for discussion of SLNB
Surgical margin determination – Breslow depth determines the required wide local excision (WLE) margin (0.5 cm for in situ, 1.0 cm for ≤1.0 mm, 1.0-2.0 cm for 1.01-2.0 mm, 2.0 cm for >2.0 mm)
Prognostic counseling – Provides quantitative estimate of recurrence and survival risk (e.g., T1a ≤0.8 mm, no ulceration: 5-year survival 99%; T4b >4.0 mm with ulceration: 5-year survival ~50-60%)
Adjuvant therapy decisions – For resected stage III melanoma (positive SLNB), Breslow depth of primary is one factor in recurrence risk assessment (along with number of positive nodes, ulceration, and nodal burden)
Clinical trial eligibility – Many adjuvant therapy trials (immunotherapy, targeted therapy) use Breslow depth and SLNB status as inclusion criteria
Research and quality measurement – Standardized reporting across institutions enables meta-analyses, guideline development, and benchmarking

Anatomical Principles: How Breslow Depth is Measured

Key measurement rules (AJCC 8th Edition, CAP protocol): • Start point: Top of the granular layer of the epidermis (the stratum granulosum, just below the stratum corneum). If the epidermis is ulcerated (loss of epithelium), measure from the base of the ulcer (the tumor-air interface), not from the presumed original granular layer. • End point: The deepest continuous or non-continuous tumor cell at the leading invasive front. Include satellite tumor nests, single cells, and tumor cells tracking along adnexal structures (hair follicles, sweat glands, sebaceous glands). Do NOT include inflammatory cells, fibrosis, or non-tumoral melanin-laden macrophages. • Measurement tool: Ocular micrometer calibrated to the objective lens (typically 0.5 mm increments for scanning power, 0.1 mm for high power). Measure perpendicular (vertical) from the start point to the deepest invasive cell using a line perpendicular to the epidermal surface. • Multiple measurements: For tumors with irregular contours, measure from the highest point of the granular layer (or ulcer base) to the deepest invasive cell. In some cases (large desmoplastic melanoma), multiple measurements may be taken; report the greatest thickness. • Microscopic satellites: Tumor nests separated from the main mass by normal tissue (not fibrosis) should be included in the measurement if they are within 0.5 mm of the main invasive front. If beyond 0.5 mm, they are counted separately as microsatellitosis (upstages to N stage, not T).

Comparison with Clark Level

FeatureBreslow DepthClark Level
DefinitionVertical tumor thickness in millimeters from granular layer (or ulcer base) to deepest invasive cellAnatomic level of invasion (I-V) based on dermal layers
Levels/CategoriesContinuous variable (0.1 to 20+ mm), categorized into AJCC T categories (T1-T4)5 ordinal levels: I (intraepidermal), II (papillary dermis), III (papillary-reticular interface), IV (reticular dermis), V (subcutaneous fat)
Inter-observer reliabilityHigh (0.85-0.95 correlation coefficient, precise measurement)Low to moderate (kappa 0.45-0.65, subjective boundaries of dermal layers)
Prognostic powerSuperior (single most important prognostic factor per AJCC)Inferior (no longer used in AJCC 8th Edition for T staging, but may be reported for historical completeness)
Use in AJCC 8th EditionPrimary determinant of T category (T1-T4 based on thickness and ulceration)Not used in formal staging (dropped after AJCC 5th Edition in 2001)
Correlation with SLNB positivityContinuous: 5% (≤0.8 mm), 10-15% (0.8-1.0 mm), 15-25% (1.01-2.0 mm), 30-45% (2.01-4.0 mm), >50% (>4.0 mm)Clark IV/ V higher risk than Clark II/III, but does not add independent prognostic information after adjusting for Breslow
Clinical utility (2024)Essential for staging, margins, SLNB decision, and adjuvant therapyHistorical; rarely used in modern clinical decision-making except for T1a classification (≤0.8 mm AND no ulceration AND Clark level IV may upstage to T1b? Controversial; NCCN does not recommend)

AJCC 8th Edition T Categories (2018, updated with data from 13,000+ patients)

T CategoryBreslow Depth (mm)Ulceration StatusEstimated 5-year Survival (Stage I-II)SLNB Positivity RateManagement Implications
Tis (in situ)N/A (no invasion; melanoma confined to epidermis)Not applicable~99-100%<1% (rarely positive)Wide local excision with 0.5-1.0 cm margins, no SLNB, no adjuvant therapy. Complete excision is curative.
T1a≤0.8 mmNo ulceration~99% (similar to Tis)~5-7% (low, but not zero)WLE with 1.0 cm margins. SLNB may be considered if mitotic rate ≥1/mm², lymphovascular invasion, or patient young age (but NCCN: discussion for T1b only). Controversial; most guidelines do NOT recommend routine SLNB for T1a.
T1b≤1.0 mmYes (ulceration) OR 0.8-1.0 mm regardless of ulceration~97-98%~10-15% (higher if ulcerated)WLE with 1.0 cm margins. SLNB recommended for discussion (NCCN: consider SLNB for T1b, especially if ulcerated or high mitotic rate). Adjuvant therapy not standard (unless SLNB positive).
T2a1.01 - 2.0 mmNo ulceration~93-96%~15-20%WLE with 1.0-2.0 cm margins (1 cm acceptable, 2 cm preferred by some). SLNB indicated (NCCN Category 1 recommendation). If SLNB negative, observation. If SLNB positive, complete lymph node dissection or nodal observation (MSLT-II trial), consider adjuvant immunotherapy.
T2b1.01 - 2.0 mmYes (ulceration)~90-93%~25-30%Same as T2a but higher risk; SLNB mandatory. Adjuvant therapy if SLNB positive. Consider baseline imaging (CXR, LDH) due to higher risk.
T3a2.01 - 4.0 mmNo ulceration~85-90%~30-40%WLE with 2.0 cm margins. SLNB indicated (Category 1). Baseline imaging (CXR, LDH, CT chest/abdomen/pelvis if high-risk symptoms or for clinical trial). Adjuvant therapy if SLNB positive.
T3b2.01 - 4.0 mmYes (ulceration)~75-85%~40-50%Same as T3a but higher risk. Baseline imaging recommended (CT or PET-CT) even if SLNB negative (due to higher distant metastasis risk).
T4a>4.0 mmNo ulceration~70-80%~50-65%WLE with 2.0 cm margins. SLNB indicated. Baseline imaging required (CT chest/abdomen/pelvis or PET-CT). Consider adjuvant immunotherapy even if SLNB negative? NCCN: For T4 (≥4 mm), consider adjuvant therapy discussion if high risk (ulcerated, positive SLNB, multiple primaries).
T4b>4.0 mmYes (ulceration)~50-60%~65-75%Same as T4a. Very high risk. SLNB mandatory. Baseline imaging required. Strongly consider adjuvant immunotherapy (anti-PD-1, e.g., pembrolizumab, nivolumab) even if SLNB negative (based on extrapolation from stage III trials and high recurrence risk). Clinical trial if available.

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the Clark Level, Sentinel Lymph Node Biopsy, AJCC Melanoma Staging or the Molecular Melanoma Risk to formulate a comprehensive care plan.

Last Comprehensive Review: 2026

Related Pathology Tools

Fractional Excretion of Sodium
Corrected Calcium
Delta-Delta Ratio
Fractional Excretion of Urea
Calculated Serum Osmolality
Bethesda System
Serum Anion Gap
Corrected Sodium
Partin Tables
Pathology CalculatorsInternal Medicine CalculatorsEmergency Medicine Calculators
Have feedback about this calculator?Let us know.